Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies

被引:0
作者
Ramos-Martinez, Espiridion [1 ]
Rodriguez-Vega, Eric A. [2 ]
Rivera-Matias, Pedro A. [2 ,3 ]
Falfan-Valencia, Ramces [4 ]
Perez-Rubio, Gloria [4 ]
Mejia, Mayra [2 ]
Gonzalez-Perez, Montserrat I. [2 ]
Buendia-Roldan, Ivette [5 ]
Mateos-Toledo, Heidegger N. [2 ]
Serrano, Jorge Rojas [2 ,6 ]
机构
[1] Univ Nacl Autonoma Mexico, Fac Med, Expt Med Res Unit, Mexico City, Mexico
[2] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Interstitial Lung Dis & Rheumatol Unit, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[3] Becario Direcc Gen Calidad & Educ Salud, Mexico City, Mexico
[4] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[5] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Res Direct, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[6] Univ Nacl Autonoma Mexico, Fac Med, Programa Maestria & Doctorado Ciencias Med, Mexico City, Mexico
来源
MEDICINA CLINICA | 2023年 / 161卷 / 12期
关键词
Interstitial lung disease; Anti-MDA5; Nonspecific interstitial pneumonia; Inflammatory myopathies; DERMATOMYOSITIS PATIENTS; ANTIBODY; MDA5; RECOGNITION; EXPRESSION;
D O I
10.1016/j.medcli.2023.07.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The anti-MDA5-associated autoimmune disease represents a poorly understood entity. The study's objectives were to describe a cohort of interstitial lung disease (ILD) patients who were positive for anti-MDA5 autoantibody and identify clinical risk factors associated with survival. Methods: This single-center cohort study included ILD patients positive for anti-MDA5 autoantibody. Baseline clinical features were registered, and survival analysis was performed to identify risk factors associated with worse survival. Results: Fifty-three ILD-MDA5 positive patients were included; twelve died during follow-up due to rapidly progressive interstitial lung disease (RP-ILD). Dermatological signs of anti-MDA5 (Gottron papules, Gottron sign, palmar papules, V-neck sign, facial dermatomyositis rashes, and skin ulcers) were strongly associated with death secondary to RP-ILD (HR: 3.7, 95% CI: 1.02-13.35). Patients with dermatological signs were younger, had higher anti-MDA5 autoantibodies titers, more frequent inflammatory patterns in HRCT evaluation, and less fibrosis extent in HRCT. Conclusion: Dermatological manifestation in ILD patients to anti-MDA5 autoantibodies are associated with RP-ILD and short-term fatal outcomes. Dermatological signs may identify a subgroup of ILD-positive to anti-MDA5 patients with a high risk of RP-ILD. (c) 2023 Elsevier Espan similar to a, S.L.U. All rights reserved.
引用
收藏
页码:515 / 522
页数:8
相关论文
共 50 条
  • [31] Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age
    Yamaguchi, Koichi
    Yamaguchi, Aya
    Onuki, Yuji
    Itai, Miki
    Kashiwagi, Chiharu
    Takehara, Kazutaka
    Aoki, Shuhei
    Kanaya, Azusa
    Taguchi, Kohei
    Umetsu, Kazue
    Oshima, Kazuma
    Uchida, Megumi
    Kimura, Hayato
    Kasahara, Morimitsu
    Takemura, Masao
    Hara, Kenichiro
    Sekiguchi, Akiko
    Motegi, Sei-ichiro
    Muro, Yoshinao
    Nakasatomi, Masao
    Motohashi, Rena
    Sakairi, Toru
    Nakagawa, Junichi
    Hiromura, Keiju
    Obokata, Masaru
    Kurabayashi, Masahiko
    Maeno, Toshitaka
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 177 - 185
  • [32] Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease
    Intapiboon, Porntip
    Siripaitoon, Boonjing
    RESPIRATORY MEDICINE CASE REPORTS, 2020, 31
  • [33] Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis
    Yun Peng
    Suhan Zhang
    Yi Zhao
    Yi Liu
    Bing Yan
    Clinical Rheumatology, 2018, 37 : 107 - 115
  • [34] An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years
    Sato, Yuki
    Otsuka, Kojiro
    Tamai, Koji
    Ono, Yuichiro
    Hamaguchi, Yasuhito
    Tomii, Keisuke
    INTERNAL MEDICINE, 2017, 56 (03) : 341 - 346
  • [35] Multidisciplinary approach to anti-MDA5 antibody-positive dermatomyositis associated with rapidly progressive interstitial lung disease
    Witkowska, Anna Barbara
    Cowley, Sharon
    Dempsey, Philip
    Stack, John
    BMJ CASE REPORTS, 2022, 15 (03)
  • [36] A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis
    Xu, Wenwen
    Wu, Wanlong
    Zhang, Danting
    Chen, Zhiwei
    Tao, Xinwei
    Zhao, Jiangfeng
    Wang, Kaiwen
    Wang, Xiaodong
    Zheng, Yu
    Ye, Shuang
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [37] Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report
    Kato, Sayaka
    Sakamoto, Koji
    Sato, Tomonori
    Kobayashi, Tomoko
    Shindo, Yuichiro
    Morise, Masahiro
    Iwama, Shintaro
    Arima, Hiroshi
    Ishii, Makoto
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 313 - 316
  • [38] Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy
    Abe, Yoshiyuki
    Kusaoi, Makio
    Tada, Kurisu
    Yamaji, Ken
    Tamura, Naoto
    RHEUMATOLOGY, 2020, 59 (04) : 767 - 771
  • [39] Rituximab in the treatment of anti-MDA5 dermatomyositis-associated interstitial lung disease: a case-based literature review
    Nascimento, J.
    Tenazinha, C.
    Campanilho-Marques, R.
    Cordeiro, I
    Salgado, S.
    ARP RHEUMATOLOGY, 2022, 1 (02): : 168 - 173
  • [40] Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis
    Hoshino, Kei
    Muro, Yoshinao
    Sugiura, Kazumitsu
    Tomita, Yasushi
    Nakashima, Ran
    Mimori, Tsuneyo
    RHEUMATOLOGY, 2010, 49 (09) : 1726 - 1733